For: | Alomari M, Rashid MU, Chadalavada P, Ragheb J, Zafar H, Suarez ZK, Khazaaleh S, Gonzalez AJ, Castro FJ. Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes. World J Hepatol 2023; 15(4): 477-496 [PMID: 37206648 DOI: 10.4254/wjh.v15.i4.477] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v15/i4/477.htm |
Number | Citing Articles |
1 |
Muhammed Mubarak. Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities. World Journal of Gastrointestinal Pathophysiology 2024; 15(1): 92864 doi: 10.4291/wjgp.v15.i1.92864
|
2 |
Tsutomu Hirano. Excess Triglycerides in Very Low-Density Lipoprotein (VLDL) Estimated from VLDL-Cholesterol could be a Useful Biomarker of Metabolic Dysfunction Associated Steatotic Liver Disease in Patients with Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis 2024; doi: 10.5551/jat.65164
|
3 |
Zuzana Sumbalová, Jarmila Kucharská, Zuzana Rausová, Anna Gvozdjáková, Mária Szántová, Branislav Kura, Viliam Mojto, Ján Slezák. The Effect of Adjuvant Therapy with Molecular Hydrogen on Endogenous Coenzyme Q10 Levels and Platelet Mitochondrial Bioenergetics in Patients with Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2023; 24(15): 12477 doi: 10.3390/ijms241512477
|
4 |
Giuseppina Guarino, Felice Strollo, Teresa Della Corte, Ersilia Satta, Sandro Gentile. Effect of Neo-Policaptil Gel Retard on Liver Fat Content and Fibrosis in Adults with Metabolic Syndrome and Type 2 Diabetes: A Non-invasive Approach to MAFLD. Diabetes Therapy 2023; 14(12): 2089 doi: 10.1007/s13300-023-01478-2
|